Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses; July 22, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation strategy and dividend policies during the specified Class Period [1][3]. Group 1: Class Action Details - The class action represents investors who purchased Organon securities between November 3, 2022, and April 30, 2025 [1]. - Investors have until July 22, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations Against Organon - The lawsuit claims that Organon concealed critical information about its capital allocation strategy, particularly regarding its quarterly dividend payout [3]. - Despite public statements indicating that maintaining the dividend was a top priority, Organon had adopted a debt reduction strategy that conflicted with this commitment [3]. - Following the acquisition of Dermavant Sciences Ltd., Organon intended to prioritize debt reduction, which led to a significant cut in its dividend [3]. Group 3: Financial Impact - On May 1, 2025, Organon announced a drastic reduction in its quarterly dividend from $0.28 to $0.02 per share [4]. - This announcement resulted in a stock decline of more than 27% [4].